Achievement of No Evidence of Disease Activity-3 with Oral Disease-Modifying Treatment in Patients with Relapsing–Remitting Multiple Sclerosis
More than half of the patients with relapsing-remitting multiple sclerosis on oral DMTs achieved NEDA-3 status in this study. Significant differences were observed in NEDA-3 status parameters and achievement between patients on oral DMTs and interferon, with the likeliness being highest among patients treated with dimethyl-fumarate.
Authors
- Foziah Alshamrani (ORCID: https://orcid.org/0000-0003-2837-4891)
- Saima Nazish (ORCID: https://orcid.org/0000-0003-4301-8836)
- Azra S. Zafar (ORCID: https://orcid.org/0000-0001-6027-7229)
- Nehad Mahmoud Soltan (ORCID: https://orcid.org/0000-0002-9011-7151)
- Rizwana Shahid (ORCID: https://orcid.org/0000-0001-7339-2955)
- Erum Shariff (ORCID: https://orcid.org/0000-0002-2608-1107)
- Zakia Yasawy
- Rahmah Majed Alsawad
Institutions
- King Fahd Hospital of the University (SA)
- Dar Al Uloom University (SA)
Publication Details
- Journal
- Saudi Journal of Medicine and Medical Sciences
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/sjmms.sjmms_148_24
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00